New external innovation investment fund helps GSK tap in to Canadian innovation
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has today launched its $50 million Canada Life Sciences Innovation Fund that will invest in early stage breakthrough research. The firm says the fund, the first of its kind with a "dedicated mandate for Canada," will extend the GSK's collaborative focus.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.